YDES Key Statistics, Chart & Performance
The current stock price of YDES is 12 USD. In the past month the price decreased by -7.41%.
YDES Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About YDES
Company Profile
YD Bio Ltd. engages in the development of detection and therapeutic technologies. The company is headquartered in Taipei City, Taipei and currently employs 5 full-time employees. The company went IPO on 2025-08-29. The firm is focused on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of diseases with unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. The company is focused on advancing a diversified portfolio of healthcare solutions across oncology diagnostics, regenerative medicine and clinical trial support. The company is a supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. Its core programs include Blood-Based Cancer Detection, Stem Cell- and Exosome-Based Ophthalmology Therapies, and Clinical Trial and AncillaryServices. The company is developing proprietary DNA methylation-based detection technology for a range of cancers, which includes a screening test for the early detection of pancreatic cancer and a monitoring test for recurrent breast cancer.
Company Info
YD BIO LTD
12F, No. 3, Xingnan Street, Nangang District
Taipei City TAIPEI TW
Employees: 5
Phone: 88623820330
YD BIO LTD / YDES FAQ
What does YD BIO LTD do?
YD Bio Ltd. engages in the development of detection and therapeutic technologies. The company is headquartered in Taipei City, Taipei and currently employs 5 full-time employees. The company went IPO on 2025-08-29. The firm is focused on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of diseases with unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. The company is focused on advancing a diversified portfolio of healthcare solutions across oncology diagnostics, regenerative medicine and clinical trial support. The company is a supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. Its core programs include Blood-Based Cancer Detection, Stem Cell- and Exosome-Based Ophthalmology Therapies, and Clinical Trial and AncillaryServices. The company is developing proprietary DNA methylation-based detection technology for a range of cancers, which includes a screening test for the early detection of pancreatic cancer and a monitoring test for recurrent breast cancer.
What is the current price of YDES stock?
The current stock price of YDES is 12 USD. The price decreased by -1.56% in the last trading session.
What is the dividend status of YD BIO LTD?
YDES does not pay a dividend.
How is the ChartMill rating for YD BIO LTD?
YDES has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How many employees does YD BIO LTD have?
YD BIO LTD (YDES) currently has 5 employees.
What is YD BIO LTD worth?
YD BIO LTD (YDES) has a market capitalization of 846.24M USD. This makes YDES a Small Cap stock.
YDES Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to YDES.
YDES Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to YDES. While YDES seems to be doing ok healthwise, there are quite some concerns on its profitability.
YDES Financial Highlights
Over the last trailing twelve months YDES reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS decreased by -10100% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.17% | ||
| ROE | -27.74% | ||
| Debt/Equity | 0 |